These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 29187090)
1. Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation. Banerjee D; Roeker LE; Grogan M; Swiecicki P; Poterucha J; Heimbach J; Zeldenrust S; Gertz M; Edwards B; Daly R; Klarich KW; Dispenzieri A Prog Transplant; 2017 Sep; 27(3):246-250. PubMed ID: 29187090 [TBL] [Abstract][Full Text] [Related]
2. Evaluating Prognostic Factors for Liver Transplantation Among United States Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis Using National Registry Data. Brandman D; Lin H; McManus A; Agarwal S; Gache LM; Irish W; Gollob J; Živković SA Prog Transplant; 2019 Sep; 29(3):213-219. PubMed ID: 31167608 [TBL] [Abstract][Full Text] [Related]
3. Liver transplantation in transthyretin amyloidosis: issues and challenges. Carvalho A; Rocha A; Lobato L Liver Transpl; 2015 Mar; 21(3):282-92. PubMed ID: 25482846 [TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of patients with hereditary transthyretin V30M amyloidosis with polyneuropathy after liver transplantation. Okumura K; Yamashita T; Masuda T; Misumi Y; Ueda A; Ueda M; Obayashi K; Jono H; Yamashita S; Inomata Y; Ando Y Amyloid; 2016; 23(1):39-45. PubMed ID: 26763274 [TBL] [Abstract][Full Text] [Related]
5. Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative? Ericzon BG; Wilczek HE; Larsson M; Wijayatunga P; Stangou A; Pena JR; Furtado E; Barroso E; Daniel J; Samuel D; Adam R; Karam V; Poterucha J; Lewis D; Ferraz-Neto BH; Cruz MW; Munar-Ques M; Fabregat J; Ikeda S; Ando Y; Heaton N; Otto G; Suhr O Transplantation; 2015 Sep; 99(9):1847-54. PubMed ID: 26308415 [TBL] [Abstract][Full Text] [Related]
6. Rapidly Progressive Transthyretin-Mediated Amyloidosis in a Domino Liver Transplant Recipient of a Ser23Asn Donor. Dixit N; Castano A; Farr MJ; Traub R; Lentzsch S; Brown RS; Maurer MS; Brannagan TH J Clin Neuromuscul Dis; 2016 Mar; 17(3):142-5. PubMed ID: 26905915 [TBL] [Abstract][Full Text] [Related]
7. Outcome in patients treated with isolated liver transplantation for familial transthyretin amyloidosis to prevent cardiomyopathy. Nelson LM; Penninga L; Villadsen GE; Mølgaard H; Eiskjaer H; Hillingsø JG; Rasmussen A Clin Transplant; 2015 Dec; 29(12):1098-104. PubMed ID: 26361241 [TBL] [Abstract][Full Text] [Related]
8. Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy. Algalarrondo V; Antonini T; Théaudin M; Chemla D; Benmalek A; Castaing D; Cauquil C; Rouzet F; Mika D; Duong E; Dinanian S; Eliahou L; Le Guludec D; Samuel D; Adams D; Slama MS Amyloid; 2018 Dec; 25(4):253-260. PubMed ID: 30632809 [TBL] [Abstract][Full Text] [Related]
18. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Herlenius G; Wilczek HE; Larsson M; Ericzon BG; Transplantation; 2004 Jan; 77(1):64-71. PubMed ID: 14724437 [TBL] [Abstract][Full Text] [Related]
19. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Barreiros AP; Post F; Hoppe-Lotichius M; Linke RP; Vahl CF; Schäfers HJ; Galle PR; Otto G Liver Transpl; 2010 Mar; 16(3):314-23. PubMed ID: 20209591 [TBL] [Abstract][Full Text] [Related]
20. Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients. Conceição I; Miranda B; Castro J; de Carvalho M Eur J Neurol; 2018 Nov; 25(11):1320-e115. PubMed ID: 29924456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]